SATuRN and BioAfrica open access reports:

Here we provide you with sections from our open access annual reports, which are directed at public health practitioners, policies makers, doctors, researchers and the general public.

The objective of these reports is to present the key aspects of our work in an accessible, summarized format. The majority of the work presented has been published in peer-reviewed publications and can be seen in the publications section of bioafrica.net.


Report Latest Reports

SATuRN and Life Technologies (ABI) partnership provide a discounted HIV resistance genotyping system

Authors: SATuRN / Life Technologies

Introduction:

Antiretroviral (ARV) drugs are becoming increasingly available to treat HIV-1 infected individuals in the developing world. The goal of many governments and non-governmental organizations is to sustain the effective ARV treatment of > 5 million people in Africa. Pharmaceutical companies are reducing both prices and international trade restrictions on patented drugs to allow more equitable access to essential medicines for AIDS, TB and Malaria. However, the widespread increase of treatment is threatened by the appearance of drug resistance.

Public health and patient benefit may be limited by the increase in selection and transmission of broadly ARV resistant viruses. Drug resistance viruses can currently be identified with genetic sequencing of two HIV-1 genes. However, the price of an individual test using commercial methods (ZAR 2,500 or US$ 300) makes it too expensive for public health implementation in southern Africa.

SATuRN HIV Resistance Genotyping:

We have developed an in-house HIV resistance genotyping system in collaboration with the Stanford HIV Drug Resistance Database team and it has been internationally validated by the French AIDS Research (French acronym: ANRS).

Our in-house sequences are generated with the Sanger ABI sequencing technology. This process involves the production of cDNA, which is reverse transcribed from the viral RNA. Our in-house genotyping test reagents currently costs around ZAR 750 (US$ 100) per sample, a great part of the cost of which ZAR560/ZAR750 (US$80/US$100) is due to the cDNA synthesis and the ABI sequencing process. SATuRN members would like to ask ABI to reduce the price of the reagents needed for HIV drug resistance genotyping for the members of our network.

Life Technologies (ABI) and SATuRN partnership:

Life Technologies has agreed to provide a 25% discount for reagents for HIV genotyping to SATuRN members. This partnership aims to produce a discounted genotypic test kit to southern African partners that will be available soon.

For the moment, partners can request discounted reagents from ABI (Seshnee Pillay, Seshnee.Pillay@lifetech.com) and the protocol and validation samples from SATuRN partners at the UFS (Dr. Dominique Goedhals, gnvrdg@ufs.ac.za) and Africa Centre (Justen Manasa, jmanasa@africacentre.ac.za).


SATuRN output, All reports...
SATuRN 2013 report - SATuRN Collaborates on a Successful Molecular Diagnostics in HIV/AIDS and Tuberculosis in Zimbabwe, 6-9 Aug 2013
SATuRN 2013 report - SATuRN and Khethimpilo HIV Drug Resistance and Clinical Management Workshop Report, Durban, 11-12 July 2013
SATuRN report 2013 - Major data analysis determines the trends of HIV-1 drug resistance mutations in South Africa.
SATuRN output, All reports...


Page design updated by Tulio de Oliveira, 2011